Omlonti

oomidenepag isopropyl ophthalmic solution

Approval

ApplicationNDA 215092
Approval dateSep 22, 2022
Approval year2022
SponsorOcuvex Therap

FDA-approved use

To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Omlonti: